A Single Arm, Open-Label Pilot Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) Stage IB to IV
What is the purpose of this trial?
Cutaneous T cell lymphoma (CTCL) is an incurable skin-homing T cell non-Hodgkin lymphoma (NHL) that may commonly have blood/leukemic and lymph node involvement. Advanced stages of CTCL are more likely to have blood/leukemic and lymph node involvement and show resistance to standard therapy. There are currently only two oral agents approved for the treatment of CTCL: bexarotene and vorinostat. Venetoclax is a newly approved oral agent for the treatment of CLL. Venetoclax has also been shown to be especially potent against NHL and AML cell lines expressing high levels of Bcl-2.6, 7 We have recently revealed that the malignant cells isolated from a cohort of CTCL patients exhibit extreme sensitivity to venetoclax by cell viability assays, with EC50 doses as low as 1-3 nM, and this sensitivity correlated with Bcl-2 expression. Thus, venetoclax is a promising candidate novel therapy for CTCL.
- Trial withAbbVie Inc.
- Start Date03/31/2019
- End Date02/27/2021
- Last Updated08/18/2020
- Study HIC#2000022803